Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds.
Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds.
复制标题
DOI：
10.18632/oncotarget.13894
复制
发表时间：
2017-01-03
期刊：
影响因子：
--
通讯作者：
Chumanevich AA
中科院分区：
文献类型：
--
作者：
Chumanevich AA;Chaparala A;Witalison EE;Tashkandi H;Hofseth AB;Lane C;Pena E;Liu P;Pittman DL;Nagarkatti P;Nagarkatti M;Hofseth LJ;Chumanevich AA
溃疡性结肠炎（UC）是一种慢性终身性结肠炎性疾病，虽然未经治疗，但具有复发和缓解过程，并增加了向结直肠癌进展的风险。目前UC的药物治疗策略主要集中在抑制UC的体征和症状，以诱导缓解和预防疾病活动复发，最大限度地减少对生活质量的影响，但不影响疾病的病因。然而，迄今为止，还没有能够在患者的整个生命中有效地控制结肠炎进展而没有副作用、缓解或抗性的单一可靠的治疗剂和/或策略。考虑到对新的结肠炎治疗策略、炎症靶点和/或调节剂的迫切需求，我们已经测试了用于结肠炎治疗的当前和前瞻性化合物，并使用葡聚糖硫酸钠（DSS）结肠炎小鼠模型直接比较了它们的抗结肠炎效力。我们引入了一个综合评分-一个多参数比较工具-来评估不同化合物的生物效力。
Ulcerative colitis (UC) is a chronic lifelong inflammatory disorder of the colon, which, while untreated, has a relapsing and remitting course with increasing risk of progression toward colorectal cancer. Current medical treatment strategies of UC mostly focus on inhibition of the signs and symptoms of UC to induce remission and prevent relapse of disease activity, minimizing the impact on quality of life, but not affecting the cause of disease. To date, however, there is no single reliable treatment agent and/or strategy capable of effectively controlling colitis progression throughout the patient's life without side effects, remission, or resistance. Taking into consideration an urgent need for the new colitis treatment strategies, targets and/or modulators of inflammation, we have tested current and prospective compounds for colitis treatment and directly compared their anti-colitis potency using a dextran sulfate sodium (DSS) mouse model of colitis. We have introduced a composite score – a multi-parameters comparison tool – to assess biological potency of different compounds.